Cite
Webster R, Sekuloski S, Odedra A, et al. Safety, infectivity and immunogenicity of a genetically attenuated blood-stage malaria vaccine. BMC Med. 2021;19(1):293doi: 10.1186/s12916-021-02150-x.
Webster, R., Sekuloski, S., Odedra, A., Woolley, S., Jennings, H., Amante, F., Trenholme, K. R., Healer, J., Cowman, A. F., Eriksson, E. M., Sathe, P., Penington, J., Blanch, A. J., Dixon, M. W. A., Tilley, L., Duffy, M. F., Craig, A., Storm, J., Chan, J. A., Evans, K., Papenfuss, A. T., Schofield, L., Griffin, P., Barber, B. E., Andrew, D., Boyle, M. J., de Labastida Rivera, F., Engwerda, C., & McCarthy, J. S. (2021). Safety, infectivity and immunogenicity of a genetically attenuated blood-stage malaria vaccine. BMC medicine, 19(1), 293. https://doi.org/10.1186/s12916-021-02150-x
Webster, Rebecca, et al. "Safety, infectivity and immunogenicity of a genetically attenuated blood-stage malaria vaccine." BMC medicine vol. 19,1 (2021): 293. doi: https://doi.org/10.1186/s12916-021-02150-x
Webster R, Sekuloski S, Odedra A, Woolley S, Jennings H, Amante F, Trenholme KR, Healer J, Cowman AF, Eriksson EM, Sathe P, Penington J, Blanch AJ, Dixon MWA, Tilley L, Duffy MF, Craig A, Storm J, Chan JA, Evans K, Papenfuss AT, Schofield L, Griffin P, Barber BE, Andrew D, Boyle MJ, de Labastida Rivera F, Engwerda C, McCarthy JS. Safety, infectivity and immunogenicity of a genetically attenuated blood-stage malaria vaccine. BMC Med. 2021 Nov 22;19(1):293. doi: 10.1186/s12916-021-02150-x. PMID: 34802442; PMCID: PMC8606250.
Copy
Download .nbib